Klinická farmakologie a farmacie – 3/2018

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2019; 33(3): 37–40 /  www.klinickafarmakologie.cz 40 PŘEHLEDOVÉ ČLÁNKY Budoucí trendy v léčbě karcinomu jícnu (prevence, biologická terapie, imunoterapie, individualizovaná terapie, novinky v chirurgii) 7. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001; 96(4): 990–996. 8. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triada­ filopoulos G. Cyclooxygenase 2 expression in Barrett's eso­ phagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000; 118(3): 487–496. 9. Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, par­ ticularly in patients with Barrett's esophagus: a systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2013; 11(6): 620–629. 10. Ganz RA, Peters JH, Horgan S, Bemelman WA, Dunst CM, Edmundowicz SA, Lipham JC, Luketich JD, Melvin WS, Oelschlager BK, Schlack-Haerer SC, Smith CD, Smith CC, Dunn D, Taiganides PA. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med. 2013; 368(8): 719–727. 11. Zadeh J, Andreoni A, Treitl D, Ben-David 1. Spotlight on the Linx™ Reflux Management System for the treatment of gastroesophageal reflux disease: evidence and research. Med Devices (Auckl). 2018; 11: 291–300. 12. Inoue H, Ito H, Ikeda H, Sato C, Sato H, Phalanusitthepha C1, Hayee B2, Eleftheriadis N1, Kudo SE3. Anti-reflux muco­ sectomy for gastroesophageal reflux disease in the absen­ ce of hiatus hernia: a pilot study. Ann Gastroenterol. 2014; 27(4): 346–351. 13. Inoue H, Sumi K, Tatsuta T, Ikebuchi Y, Tuason J. Clinical Re­ sults of Antireflux Mucosectomy (ARMS) for Refractory Gerd. Gastrointestinal Endoscopy, 2017; 85(5): AB120. 14. Chan DS, Campbell F, Edwards P, Jasani B, Williams GT, Lewis WG. Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer. ISRN Surg. 2012; 2012: 804891. 15. Van Cutsem E, Kang Y, Chung H, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard che­ motherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Jour­ nal of Clinical Oncology 27, no. 15_suppl. 16. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shi­ mada Y, Hironaka S, et al. Ramucirumab plus paclitaxel ver­ sus placebo plus paclitaxel in patients with previously trea­ ted advanced gastric or gastro-oesophageal junction ade­ nocarcinoma (RAINBOW): a double-blind, randomised pha­ se 3 trial. Lancet Oncol. 2014; 15(11): 1224–1235. 17. Ruhstaller T, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuxi­ mab in patients with resectable esophageal cancer: a ran­ domized, open-label, phase III trial (SAKK 75/08). Ann Oncol. 2018; 29(6): 1386–1393. 18. Zhang Y, Pan T, Zhong X, Cheng C. Resistance to cetuxi­ mab in EGFR-overexpressing esophageal squamous cell car­ cinoma xenografts due to FGFR2 amplification and overex­ pression. J Pharmacol Sci. 2014; 126(1): 77–83. 19. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480(7378): 480–489. 20. Razack AH. Bacillus Calmette-Guerin and bladder cancer. Asian J Surg. 2007; 30(4): 302–309. 21. Bartnik A, Nirmal AJ, Yang S. Peptide Vaccine Therapy in Colorectal Cancer. Vaccines (Basel). 2013; 1(1): 1–16. Published online 2012 Aug 23. 22. Kono K, et al. Multicenter, phase II clinical trial of can­ cer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. Journal of Translational Medicine2012; 10: 14. 23. Bujas T, Marusic Z, Peric Balja M, Mijic A, Kruslin B, Tomas D. MAGE-A3/4andNY-ESO-1antigensexpression inmetastaticeso­ phagealsquamouscellcarcinoma.EurJHistochem.2011;55(1):e7. 24. Kageyama S. Adoptive Transfer of MAGE-A4 T-cell Recep­ tor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clin Cancer Res. 2015; 21(10): 2268–2277. 25. Pardoll DM. The blockade of immune checkpoints in ca­ ncer immunotherapy. Nature Reviews. Cancer. March 2012; 12(4): 252–264. 26. Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Saraf S, Koshiji M. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizu­ mab (MK-3475). Journal of Clinical Oncology 34, no. 4_suppl (February 1 2016) 7–7. 27. Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA, Yamaguchi K, Balogh A, Sanchez T, Moehler M. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supporti­ ve Care for Unresectable Locally Advanced/Metastatic Gas­ tric or Gastroesophageal Junction Cancer. Clin Cancer Res. 2017; 23(19): 5671–5678. 28. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Shar­ ma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Ca­ ncer. J Clin Oncol. 2018; 36(28): 2836–2844. 29. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Phar­ macogenomics and Individualized Drug Therapy. Annual Re­ view of Medicine, 2006; 57(1): 119–137. 30. Yao Y, He Y, Han X, Ji C, Hu B. Clinical research of individu­ alized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype. Oncology Letters. 2018. 31. Künzli HT, van Berge Henegouwen MI, Gisbertz SS, van Esser S, et al. Pilot-study on the feasibility of sentinel node navigation surgery in combination with thoracolaparosco­ pic lymphadenectomy without esophagectomy in early esophageal adenocarcinoma patients. Dis Esophagus. 2017; 30(11): 1–8.